Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

Socrates E. Papapoulos(Leiden University Medical Center), Deborah M. Gurner(Merck & Co., Inc., Rahway, NJ, USA (United States)), José Zanchetta(Universidad del Salvador), A. Lombardi, Tomoko Nakamura, Jean‐Yves Reginster(King Saud University), JA Rodriguez-Portales, HG Bone, Jes s Walliser, McClung, A. Rybak-Feiglin, Celine Le Bailly De Tilleghem, Kurt Lippuner(University of Bern), C. Roux(Hôpital Pasteur), Nadia Verbruggen(Merck & Co., Inc., Rahway, NJ, USA (United States)), CA DaSilva, Dosinda Cohn(Merck & Co., Inc., Rahway, NJ, USA (United States)), IR Reid, CA Zerbini, SK Lim, DP Kiel, KG Saag, T. de Villiers, P.S. Kumar, Albert Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. Adámi, BB Scott, B.L. Langdahl, Awc Kung(University of Hong Kong), N B Watts, C. Mautalén, A. Santora, Xuefeng B. Ling(University of Pittsburgh)

Open Repository and Bibliography (University of Liège)

January 1, 2014

Cited by 2

|New England Journal of Medicine|2001|4.6k

|New England Journal of Medicine|2009|3.5k

|Osteoporosis International|2012|2.9k

|Osteoporosis International|2018|1.8k

|New England Journal of Medicine|2014|1.2k

Related Papers